[Pharmaco-economic aspects of antibiotic therapy in hospitals].
Amongst medications used in hospitals, antibiotics represent the most expensive therapeutic group; their use is constantly growing. Beyond acquisition costs, antibiotherapy costs must be approached at a broader level, including costs of preparation, administration, efficacy or inefficacy, monitoring, side effects treatment, and long-term costs resulting bacteria resistance. An attempt to cost containment in antibiotherapy can only result from a global, multidisciplinary strategy, with at all levels, as main objectives, the improvement of the quality and effectiveness of treatment adequate relevance of drug selection and therapy assessment.
Service de Pharmacie, Université de Liège.
J P
JP
Delporte
D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use; D002985:Clinical Protocols; D003363:Cost Control; D003365:Costs and Cost Analysis; D016527:Drug Costs; D016903:Drug Monitoring / Q000191:economics; D004352:Drug Resistance, Microbial; D004363:Drug Utilization; D004469:Economics, Hospital; D017850:Economics, Pharmaceutical; D006801:Humans; D011787:Quality of Health Care; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents